Comparing Toremifene and Tamoxifen for Breast Cancer Treatment
Author Information
Author(s): S Pyrhonen, R Valavaara, H Modig, M Pawlicki, T Pienkowski, S Gundersen, J Bauer, G Westman, S Lundgren, G Blanco, O Melia, I Nilsson, T Hietanen, I Hindy, J Vuorinen, A Hajba
Hypothesis
Is toremifene as effective and safe as tamoxifen in treating post-menopausal patients with advanced breast cancer?
Conclusion
Toremifene and tamoxifen are equally effective and safe for treating advanced breast cancer in post-menopausal women.
Supporting Evidence
- The response rate for toremifene was 31.3% and for tamoxifen was 37.3%.
- The median time to progression was 7.3 months for toremifene and 10.2 months for tamoxifen.
- Toremifene had a lower discontinuation rate due to adverse events compared to tamoxifen.
- Both treatments were well tolerated with mild to moderate adverse effects.
Takeaway
This study looked at two medicines for breast cancer and found that they work just as well as each other.
Methodology
A double-blind, randomized trial comparing toremifene and tamoxifen in 415 post-menopausal patients with advanced breast cancer.
Potential Biases
Potential imbalance in estrogen receptor levels between treatment groups.
Limitations
The study had a high proportion of patients with unknown estrogen receptor status, which may have affected the results.
Participant Demographics
Post-menopausal women with advanced breast cancer, aged 33.6 to 87.6 years.
Statistical Information
P-Value
0.215
Confidence Interval
-15.1% to 3.1%
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website